Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 7;15(1):160.
doi: 10.1038/s41408-025-01368-9.

Outcomes of older patients with TP53-mutated myeloid neoplasms

Omer Jamy  1 , Mobachir El Kettani  2 , Kashish Shah  2 , Rory M Shallis  3 , Kendall Diebold  1 , Alexander Coltoff  4 , Aaron D Goldberg  5 , Anand Patel  6 , Jan P Bewersdorf  3 , Charles Foucar  7 , Yasmin Abaza  8 , Neil Palmisiano  9 , Adam S DuVall  6 , Vamsi Kota  10 , Shyam A Patel  11 , Amer M Zeidan  3 , Ehab Atallah  12 , Mark R Litzow  13 , Talha Badar  14
Affiliations

Outcomes of older patients with TP53-mutated myeloid neoplasms

Omer Jamy et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: OJ; Advisory board for Ascentage, Sobi, Maat, and TERN, AP; Research funding from Kronos Bio, Sumitomo, Servier, Incyte, Pfizer; Honoraria for advisory boards from Sobi, AbbVie. CF; Advisory board, Stemline, and Honoraria from Binaytara Foundation. CL; Advisory board for ADC Therapeutics, Autolus, Consulting: Rigel. SAP served on the Acute Leukemia Advisory Board for Syndax and the MDS Advisory Board for Bristol Myers Squibb. Ethics approval and consent to participate: This study was conducted following approval from the Institutional Review Board (IRB #21-002315) and in accordance with the ethical principles outlined in the Declaration of Helsinki (1975, as revised in 2000). Informed consent was waived due to the retrospective nature of the study.

Figures

Fig. 1
Fig. 1. Survival in older patients with TP53-mutated AML.
A Kaplan–Meier curve showing event-free survival of all patients, B overall survival of all patients, and C overall survival of the subgroup who underwent allogeneic hematopoietic cell transplantation.
See this image and copyright information in PMC

References

    1. Zeidner JF, Sallman DA, Récher C, Daver NG, Leung AY, Hiwase DK, et al. Magrolimab plus azacitidine vs physician’s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025;146:590–600. - PubMed
    1. Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, et al. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood. 2023;141:1087–91. - PubMed
    1. Jamy O, Diebold K, Davis K, Bachiashvili K, Rangaraju S, Vachhani P, et al. Impact of induction intensity and transplantation on outcomes of patients with complex karyotype and TP53-mutated acute myeloid leukemia. Bone Marrow Transpl. 2023;58:823–5. - PubMed
    1. Tefferi A, Abdelmagid M, Loscocco GG, Fathima S, Begna KH, Al-Kali A, et al. TP53 mutations in myeloproliferative neoplasms: context-dependent evaluation of prognostic relevance. Am J Hematol. 2025;100:552–60. - PMC - PubMed
    1. Döhner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:2169–73. - PubMed

LinkOut - more resources